热线电话: 021-34661275
产品分类/PRODUCT CLASSIFICATION

上海细胞库

人源细胞系| 稳转细胞系| 基因敲除株| 基因点突变细胞株| 基因过表达细胞株| 重组细胞系| 猪的细胞系| 马细胞系| 兔的细胞系| 犬的细胞系| 山羊的细胞系| 鱼的细胞系| 猴的细胞系| 仓鼠的细胞系| 狗的细胞系| 牛的细胞| 大鼠细胞系| 小鼠细胞系| 其他细胞系|

原代细胞

原代细胞| 永生化细胞|

细胞培养

血清| 无血清冻存| 细胞培养试剂盒| 普通培养基| 完全培养基| 细胞污染预防| 细胞污染清除| 细胞培养辅助试剂|

细胞服务

STR鉴定服务| ATCC代购服务|

酶联试剂盒

人ELISA试剂盒| 大鼠ELISA试剂盒| 小鼠ELISA试剂盒| 兔ELISA试剂盒| 猪ELISA试剂盒| 鱼ELISA试剂盒| 牛ELISA试剂盒| 犬ELISA试剂盒| 鸭ELISA试剂盒| 豚鼠ELISA试剂盒| 鸡ELISA试剂盒| 绵羊ELISA试剂盒| 山羊ELISA试剂盒| 仓鼠ELISA试剂盒| 植物ELISA试剂盒| 药残留类试剂盒| 其他ELISA试剂盒|

生化试剂盒

生化试剂盒| 微量法检测盒| 分光法检测盒| 胶体金检测盒|

PCR试剂盒

荧光探针PCR试剂盒| 染料荧光PCR试剂盒| 核酸扩增/纯化| 普通PCR检测试剂盒| 质粒菌种感受态|

抗体蛋白

蛋白多肽| 抗体| 免疫组化| 免疫球蛋白|

试剂耗材

标准试液| 科研试剂| 缓 冲 液| 实验耗材| 高效液相色谱对照品|

首页 > 抗体蛋白 > 抗体
PE/Cyanine7 anti-mouse CD62L Antibody
产品名称：
PE/Cyanine7 anti-mouse CD62L Antibody
产品类别：
抗体
产品编号：
104417
产品应用：
104417
[价格]
规格 价格 库存
25µg ￥ 1056 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 ?g per 106 cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Ye ZW, et al. 2022. Cell Mol Immunol. 19:588. PubMed
  2. Bruggemann TR, et al. 2022. iScience. 25:105185. PubMed
  3. Oh–Hora M, et al. 2019. J Immunol. 202:2616. PubMed
  4. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  5. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  6. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  7. Gerber AN, et al. 2021. Cell Rep. 37:109816. PubMed
  8. Bhatt K, et al. 2018. mSphere. 3:e00352. PubMed
  9. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  10. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  11. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
  12. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  13. Huang W, et al. 2014. J Immunol. 193:2267. PubMed
  14. Wu J, et al. 2020. Cell Reports. 31(1):107484. PubMed
  15. Kinder JM, et al. 2020. Cell Reports. 31(12):107784.. PubMed
  16. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  17. Nguyen T, et al. 2017. Clin Transl Immunology. 10.1038/cti.2017.4. PubMed
  18. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  19. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  20. LaFleur MW, et al. 2019. Nat Immunol. 20:1335. PubMed
  21. Wu J, et al. 2020. Sci Adv. 6:eaba3458. PubMed
  22. Gordon RA, et al. 2020. PLoS One. 15:e0226396. PubMed
  23. Li B, et al. 2015. Sci Rep. 5: 14793. PubMed
  24. Hirose M, et al. 2011. Biochem Biophys Res Commun. 414:437. PubMed
  25. Zhang H, et al. 2020. Cancer Cell. 37(1):37-54.e9.. PubMed
  26. Cheng K, et al. 2021. Nat Commun. 12:2041. PubMed
  27. Geiger R, et al. 2016. Cell. 167:829-842. PubMed
  28. He X, et al. 2021. Small. 17:e2007165. PubMed
  29. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  30. Canton J, et al. 2021. Nat Immunol. 22:140. PubMed
  31. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  32. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  33. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  34. Hu Y, et al. 2022. J Nanobiotechnology. 20:417. PubMed
  35. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  36. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  37. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  38. Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed
  39. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  40. Stenstr?m M, et al. 2010. Int Immunopharmacol. 10:837. PubMed
  41. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  42. Place D, et al. 2017. PLoS One. 10.1371/journal.pone.0190384. PubMed
  43. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  44. DiPiazza AT, et al. 2021. Immunity. 54(8):1869-1882.e6. PubMed
  45. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  46. Masiuk KE, et al. 2019. Cell Stem Cell. 24:309. PubMed
  47. Horkova V, et al. 2020. Cell Reports. 30(5):1504-1514.e7.. PubMed
  48. Li G, et al. 2021. Front Oncol. 11:734593. PubMed
  49. Corbett KS, et al. 2020. Nature. 586:567. PubMed
  50. Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed
  51. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  52. Yu X, et al. 2019. Nat Commun. 10:574. PubMed
  53. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  54. Severance AL, et al. 2022. iScience. 25:104400. PubMed
  55. Robinett RA et al. 2018. Cell systems. 7(1):41-48 . PubMed
  56. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  57. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  58. Hamaidi I, et al. 2020. Cell Metabolism. 32(3):420-436.e12. PubMed
  59. Martina M, et al. 2016. J Am Soc Nephrol. 27: 1113-1123. PubMed
  60. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  61. Motwani MP, et al. 2018. JCI Insight. 3:e94463. PubMed
  62. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  64. Werner A, et al. 2021. iScience. 24:103076. PubMed
  65. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
  66. Danzer H, et al. 2020. Elife. 9:00. PubMed
  67. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  68. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  69. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  70. Xu C, et al. 2021. Cell Reports. 35(11):109235. PubMed
  71. Kitamoto S, et al. 2020. Cell. 182(2):447-462.e14. PubMed
  72. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  73. Seeling M, et al. 2013. Proc Natl Acad Sci U S A. 110:10729. PubMed
  74. Gonzalez MM, et al. 2021. J Clin Invest. 131:. PubMed
  75. Hu Y, et al. 2021. J Nanobiotechnology. 19:416. PubMed
  76. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  77. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  78. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  79. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  80. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  81. BJ L, et al. 2017. J Exp Med . 10.1084/jem.20161461. PubMed
  82. Mohammed RN, et al. 2019. Sci Rep. 4.185416667. PubMed
RRID
AB_313102 (BioLegend Cat. No. 104417) AB_313103 (BioLegend Cat. No. 104418)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org

联系我们

TEL：021-34661275 　点击拨打热线